BMJ’s Phase III Opdualag study fails to meet endpoints
The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.
14 February 2025
14 February 2025
The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.